A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer

Published:2011-08 Issue:8 Volume:6 Page:1379-1391
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ellis Peter M.,Blais Normand,Soulieres Dennis,Ionescu Diana N.,Kashyap Meenakshi,Liu Geoff,Melosky Barb,Reiman Tony,Romeo Phillippe,Shepherd Frances A.,Tsao Ming-Sound,Leighl Natasha B.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference97 articles.

1. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group;Fossella;J Clin Oncol,2003

2. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials;NSCLC Meta-Analyses Collaborative Group;J Clin Oncol,2008

3. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

4. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group;Fossella;J Clin Oncol,2000

5. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implementation Challenges and Disparities in Molecular Testing for Patients With Stage IV NSCLC: Perspectives from an Urban Safety-Net Hospital;Clinical Lung Cancer;2023-03

2. Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study;Current Oncology;2022-12-22

3. Into That Darkness: A Heideggerian Phenomenology of Pain and Suffering;Journal of Phenomenological Psychology;2022-06-17

4. Molecular Pathology in the New Age of Personalized Medicine;Pathology - From Classics to Innovations;2021-12-08

5. Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada;Journal of Thoracic Disease;2021-09